The monoclonal anti-CD52 antibody alemtuzumab is active against chronic lymphocytic leukemia and other low-grade B-and T-cell lymphoproliferative diseases. It is lymphoablative, making patients susceptible to opportunistic infections. Reactivation of cytomegalovirus (CMV) infection occurs in 10-100% of cases, depending on the patient population, the frequency and the sensitivity of the virologic surveillance tests employed.
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Until lately, relatively ineffective drugs including acyclovir, valaciclovir or famciclovir have been used as CMV prophylaxis. 2 Recently, it has been reported that valganciclovir at 450 mg twice daily prevented CMV reactivation.
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In an earlier study, we found CMV reactivation in all 10 patients given alemtuzumab.
1 An update of this series of 12 patients (Supplementary file 1), given acyclovir or valaciclovir prophylaxis, showed CMV reactivation in all of them, as evidenced by positive PCR and pp65 antigenemia. There was one fatality due to CMV pneumonitis.
From 2005 onward, valganciclovir prophylaxis was administered to all patients given alemtuzumab. There were 18 Chinese patients (Supplementary file 2) who received a median dose of 300 mg (30-1800) of alemtuzumab. Valganciclovir prophylaxis was 900 mg daily three times per week in 16 patients, 900 mg daily two times per week in one patient and 900 mg daily in one patient, from the commencement of alemtuzumab to 2 months after treatment cessation. CMV status was monitored by weekly PCR and pp65 antigen assay.
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Severe lymphopenia (median nadir lymphocyte count: 0 (0-0.9) Â 10 9 per l) developed in 17 patients. In the only case without lymphopenia, nearly all the lymphocytes were large granular lymphocyte leukemia cells. Neutropenia (o1 Â 10 9 per l) developed in four cases. In two patients, neutropenia was related to the underlying diseases (stage IV chronic lymphocytic leukemia and CD4 þ CD56 þ hematodermic malignancy), and valganciclovir was continued. In two patients, neutropenia occurred about 2 weeks after concomitant chemotherapy and blood counts recovered after cessation of valganciclovir.
During valganciclovir prophylaxis, no patients developed CMV reactivation. Sixteen patients completed valganciclovir prophylaxis without CMV reactivation. Prophylaxis was interrupted in two cases, because of neutropenia and pneumonia. CMV reactivation occurred 1 and 6 weeks later. Both responded to foscarnet and valganciclovir/ganciclovir treatment.
Our results showed that valganciclovir 900 mg three times weekly successfully prevented CMV reactivation. We used PCR to exclude CMV reactivation, 1 underlining the effectiveness of our regimen in preventing even minute degrees of CMV reactivation. Furthermore, among various racial groups, Asian patients have the highest incidence of CMV reactivation after chemotherapy and hematopoietic stem cell transplantation.
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Even in this high-risk group, our regimen totally prevented CMV reactivation.
Valganciclovir is expensive and potentially myelosuppressive. Valganciclovir 900 mg three times per week entails much cost saving and a reduced risk of neutropenia as compared with a daily regimen as reported. Chang et al. 1 reported the frequent expression of C-Maf nuclear oncoprotein in multiple myeloma (MM), not only in patients positive for the t(14;16) (q32;q23), which results in an upregulation of C-Maf, but also in a considerable proportion (25%) of t(14;16)-negative patients. Here, we have studied MafB oncoprotein expression in MM patient samples, starting with samples tested for the t(14;20) (q32;q12) by fluorescence in situ hybridization (FISH) analysis.
2 As a result, we only found protein expression of MafB confined to t(14;20)-positive patients. This is remarkable, as primary translocations involving MafB and CMaf are grouped together according their expression and correlation of high CYCLIN D2 activity and poor prognosis in MM (reviewed in Chng et al.
3 ). As a result of the t(14;20) translocation, MafB is translocated to the immunoglobulin (Ig) heavy chain locus on chromosome 14, juxtaposed to the strong IgH-Ea enhancer, resulting in oncogenic overexpression of MafB. Primary translocations are major events in MM with a prevalence of about 40%.
Maf genes form a distinct group of bZIP (basic leucine zipper) transcription factors and belong to the AP-1 super family. Members from the large Maf group can form homo-and heterodimers with other members of bZIP transcription factors 
